Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
The world is in midst of the COVID-19 pandemic. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021. This variant has a large number of mutations, some of which are concerning. Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. Below is the mutations in the spike:
Table. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes.
| Spike Mutation in SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage | Spike-S1 Subunit N Terminal | A67V | |
| Δ69-70 | |||
| T95I | |||
| G142D | |||
| Δ143-145 | |||
| Δ211-212 | |||
| ins214EPE | |||
| Spike-RBD | G339D | Important residues mutation Important residues mutation | |
| S371L | |||
| S373P | |||
| S375F | |||
| K417N | |||
| N440K | |||
| G446S | |||
| S477N | |||
| T478K | |||
| E484A | |||
| Q493R | |||
| G496S | |||
| Q498R | |||
| N501Y | |||
| Y505H | |||
| Spike-S1 Subunit | T547K | ||
| D614G | A popular mutation in different new SARS-CoV-2 lineage | ||
| H655Y | |||
| N679K | |||
| P681H | |||
| Spike-S1 Subunit | N764K | ||
| D796Y | |||
| N856K | |||
| Q954H | |||
| N969K | |||
| L981F |
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
| Cat No. | Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants | Order |
| GM-2019nCoV-PSV39 | Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529) production and Pseudovirus Based Neutralization Assay |
 |
| GM-2019nCoV-PSV40 | Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus production and Pseudovirus Based Neutralization Assay |
|
SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) & High-throughput screening (HTS) assay for efficacy evaluation and development of antiviral compounds
Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) is a target protein of antiviral compounds, which are valid for all SARS-COV-2 (2019nCOV) lineage, including Omicron variant aka B.1.1.529 lineage. The latest research shows that Pfizer’s paxlovid is effective to SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage, based on the inhibition of Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein). Thus, GeneMedi provides SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein) & High-throughput screening (HTS) assay for efficacy evaluation and development of antiviral compounds
| Cat No. | Antigen Name of 2019-nCoV(SARS-CoV-2) | Source (Expression Host) | Order |
| GMP-V-2019nCoV-Mpro001 | Recombinant 2019nCoV antigen-coronavirus Main Proteinase (Mpro, 3CLpro, His Tag) | E.coli | |
SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage neutralizing antibody
GeneMedi has quickly screened these three neutralizing antibodies, which are valid for all SARS-COV-2 (2019nCOV) lineage, including Omicron variant aka B.1.1.529 lineage. They could be used as Benchmark Antibody, assist in neutralizing antibody discovery and development.
| Cat No. | Neutralizing antibody Name | Isotypes | Order |
| GMP-V-2019nCoV-SnAb006 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | |
| GMP-V-2019nCoV-SnAb007 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | |
| GMP-V-2019nCoV-SnAb008 | Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) | Mammalian (human cell) | |
SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 diagnostic, vaccines and therapeutic antibodies
GeneMedi has quickly designed the Spike Protein RBD, Spike S-trimer Protein and Nucleocapsid protein (NP) for COVID-19 SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage to help accelerate the COVID-19 diagnostic, vaccine and therapeutic antibody discovery and development.
| Cat No. | Antigen Name of 2019-nCoV(SARS-CoV-2) | Source (Expression Host) | Order |
| GMP-V-2019nCoV-Smu-027 | Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD mutant (Omicron variant aka B.1.1.529) | Mammalian (human cell) | |
| GMP-V-2019nCoV-S-trimer-004 | Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer Protein (Omicron variant aka B.1.1.529 lineage) with furin cleavage site mutation & T4 fibritin trimerization motif | Mammalian (human cell) | |
| GMP-V-2019nCoV-N003 | Recombinant 2019-nCoV(SARS-CoV-2) Omicron variant aka B.1.1.529 Nucleocapsid Protein (N protein,N-His tag) | E.coli | |
| GMP-H-ACE2001 | Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-His) | Mammalian (human cell) | |
| GMP-H-ACE2002 | Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-FC) | Mammalian (human cell) | |
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage
GeneMedi has quickly designed the mammalian expression codon-optimized spike mutation/deletion variant vectors for COVID-19 SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development.
| Cat No. | Gene & Vector description of 2019 nCoV | Vector | Tag | Codon Optimized | Order |
| GMV-V-2019nCoV-192 | pGM-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | pcDNA3.1(+) | No tag | Codon Optimized for mamamlian | |
| GMV-V-2019nCoV-193 | Ad-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | Pre-made adenovirus | C-3FLAG | Codon Optimized for mamamlian | |
| GMV-V-2019nCoV-194 | pGMLV-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | Lentiviral vector | C-3FLAG | Codon Optimized for mamamlian | |
| GMV-V-2019nCoV-195 | pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | pcDNA3.1(+) | No tag | Codon Optimized for mamamlian | |
| GMV-V-2019nCoV-196 | Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | Pre-made adenovirus | C-3FLAG | Codon Optimized for mamamlian | |
| GMV-V-2019nCoV-197 | pGMLV-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529 | Lentiviral vector | C-3FLAG | Codon Optimized for mamamlian | |
Reference
1.https://covdb.stanford.edu/page/mutation-viewer/#omicron
